High seroprevalence of anti-SARS-CoV-2 antibodies in the capital of Chad
- PMID: 40832065
- PMCID: PMC12360175
- DOI: 10.4081/jphia.2022.2255
High seroprevalence of anti-SARS-CoV-2 antibodies in the capital of Chad
Abstract
Background: Since the start of the COVID-19 pandemic, Chad has had 7,417 confirmed cases and 193 deaths, one of the lowest in Africa.
Objective: This study assessed SARS-CoV-2 immunity in N'Djamena.
Methods: In August-October 2021, eleven N'Djamena hospitals collected outpatient data and samples. IgG antibodies against SARSCoV- 2 nucleocapsid protein were identified using ELISA. "Bambino Gesù" Laboratory, Rome, Italy, performed external quality control with chemiluminescence assay.
Results: 25-34-year-old (35.2%) made up the largest age group at 31.9±12.6 years. 56.4% were women, 1.3 women/men. The 7 th district had 22.5% and the 1st 22.3%. Housewives and students dominated. Overall seroprevalence was 69.5% (95% CI: 67.7-71.3), females 68.2% (65.8-70.5) and males 71.2% (68.6-73.8). >44-year-old had 73.9% seroprevalence. Under-15s were 57.4% positive. Housewives (70.9%), civil servants (71.5%), and health workers (9.7%) had the highest antibody positivity. N'Djamena's 9 th district had 73.1% optimism and the 3rd district had 52.5%. Seroprevalences were highest at Good Samaritan Hospital (75.4%) and National General Referral Hospital (74.7%).
Conclusion: Our findings indicate a high circulation of SARSCoV- 2 in N'Djamena, despite low mortality and morbidity after the first two COVID-19 pandemic waves. This high seroprevalence must be considered in Chad's vaccine policy.
Keywords: Anti nucleocapsid antibodies; COVID-19; N’Djamena community; SARS-CoV-2; Seroprevalence.
©Copyright: the Author(s).
Figures
References
-
- Azevedo MJ. The State of Health System(s) in Africa: Challenges and Opportunities. Hist Perspect State Heal Heal Syst Africa, Vol II. 2017. [cited 2022 Apr 27];1. Available from: 10.1007/978-3-319-32564-4_1 - DOI
-
- Mboussou F, Ndumbi P, Ngom R, Kamassali Z, Ogundiran O, Van Beek J, et al. Infectious disease outbreaks in the African region: overview of events reported to the World Health Organization in 2018. Epidemiol Infect [Internet]. 2019. Nov 11 [cited 2022 Apr 28];147:e299. Available from: https://pubmed.ncbi.nlm.nih.gov/31709961 - PMC - PubMed
-
- Fenollar F, Mediannikov O. Emerging infectious diseases in Africa in the 21st century. New microbes new Infect. 2018. Nov 1 [cited 2022 Apr 28];26:S10–8. Available from: https://pubmed.ncbi.nlm.nih.gov/30402238 - PMC - PubMed
-
- Mennechet FJD, Dzomo GRT. Coping with COVID-19 in Sub-Saharan Africa: What Might the Future Hold? Virol Sin [Internet]. 2020. Dec 1 [cited 2022 Apr 28];35(6):875. Available from: https://pubmed.ncbi.nlm.nih.gov/3287045 - PMC - PubMed
-
- Njenga MK, Dawa J, Nanyingi M, Gachohi J, Ngere I, Letko M, et al. Why is There Low Morbidity and Mortality of COVID-19 in Africa? Am J Trop Med Hyg [Internet]. 2020. Aug 1 [cited 2022 Apr 27];103(2):564. Available from: https://pubmed.ncbi.nlm.nih.gov/32484156 - PMC - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous